hepatocellular carcinoma
Conditions
Interventions
Combination Therapy Group :None
Sequential Therapy Group:None
Sponsors
Zhongshan Hospital Fudan University Xiamen Branch
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Between January 1, 2019 and January 1, 2024, those who underwent systemic therapy at participating centers in advanced inoperable resectable areas that meet the clinical diagnostic criteria of the Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2024 Edition) or the American Association of Hepatology (AASLD) Guidelines for the Diagnosis and Treatment of Liver Cancer. 2. Have at least one measurable lesion according to the efficacy evaluation criteria for solid tumors (RECIST1.1). 3. Patient age>=18 years. 4. The patient's medical history data is complete and traceable. 5. Application of systemic therapy > = 1 treatment cycle, systemic therapy includes: immune checkpoint inhibitors (including PD-(L)1, CTLA-4), TKI drugs, and macromolecule targeted therapy drugs. [Oral TKI drugs for at least 1 month.] ] 6. Combined local treatment: All combined local treatments should be reflected in the data collection to facilitate further statistical analysis of the data.
Exclusion criteria
Exclusion criteria: 1. Patients who are unable to obtain relevant examinations, examinations or follow-up information required for the study due to incomplete medical history information. 2. Child C or ECOG > 2 points 3. Less than 1 cycle of systemic treatment drugs and less than 1 month of oral targeted drugs. 4. Combined with other malignant tumors requiring active treatment; 5. Survival time at the time of enrollment < 3 months; 6. Any other conditions that, in the judgment of the investigator, consider the patient to be unsuitable for inclusion in this study;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival;Overall survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective response rate;Disease control rate;Security;Pharmacoeconomic evaluation; | — |
Countries
China
Contacts
Public ContactZhang Boheng
Zhongshan Hospital Fudan University Xiamen Branch
Outcome results
None listed